NEWS
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
Acurx Pharmaceuticals (NASDAQ: ACXP) announced results from its research on ibezapolstat in collaboration with Leiden University Medical Center (LUMC) at the International C. difficile Symposium. The research revealed high-resolution details of ibezapolstat's interaction with its molecular target, explaining its lack of cross-resistance with other antibiotics and its unique ability to not foster the emergence of Enterococcus, including vancomycin-resistant strains.
Key points:
Molecular structure data will guide the design of new systemic therapeutic compounds
Acurx is preparing to advance ibezapolstat into international Phase 3 clinical trials for C. difficile Infection (CDI) treatment
The company is seeking regulatory guidance to initiate clinical trials in the EU, UK, Japan, and Canada
Ibezapolstat has received FDA QIDP and Fast-Track Designation
Agreement reached with FDA on key elements for Phase 3 trials, including protocol design, endpoints, and safety database size
Acurx Pharmaceuticals (NASDAQ: ACXP) announced results from its research on ibezapolstat in collaboration with Leiden University Medical Center (LUMC) at the International C. difficile Symposium. The research revealed high-resolution details of ibezapolstat's interaction with its molecular target, explaining its lack of cross-resistance with other antibiotics and its unique ability to not foster the emergence of Enterococcus, including vancomycin-resistant strains.
Key points:
Molecular structure data will guide the design of new systemic therapeutic compounds
Acurx is preparing to advance ibezapolstat into international Phase 3 clinical trials for C. difficile Infection (CDI) treatment
The company is seeking regulatory guidance to initiate clinical trials in the EU, UK, Japan, and Canada
Ibezapolstat has received FDA QIDP and Fast-Track Designation
Agreement reached with FDA on key elements for Phase 3 trials, including protocol design, endpoints, and safety database size
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2467Followers
107Following
26KVisitors
Follow